ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO898

Mycophenolate Mofetil in Immunoglobulin A Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Braga, Marcelo Antonio, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  • Felix, Nicole, Universidade Federal de Campina Grande, Campina Grande, Paraíba, Brazil
  • Nogueira, Alleh, Escola Bahiana de Medicina e Saude Publica, Salvador, BA, Brazil
  • Limachi Choque, Jhonny Wilson, Universidad Mayor de San Simon, Cochabamba, Cochabamba, Bolivia, Plurinational State of
  • Oliveira, Sofia de Assis, Centro Universitario Tocantinense Presidente Antonio Carlos, Araguaina, TO, Brazil
  • Santos Pinto, Luis Claudio, Centro Universitário Metropolitano da Amazônia, Belém, Pará, Brazil
Background

Immunoglobulin A nephropathy (IgAN) is a prevalent primary glomerular disease worldwide. The efficacy of mycophenolate mofetil (MMF) for treating IgAN has yielded inconsistent findings in randomized controlled trials (RCTs).

Methods

In accordance with PRISMA guidelines, we systematically searched PubMed, Embase, Cochrane, and Web of Science in May 2023 for RCTs with long-term follow-up comparing MMF versus placebo or standard of care for IgAN with persistent proteinuria. Statistical analyses were performed using R software version 4.2.2.

Results

We included four RCTs comprising 276 patients with IgAN, of whom 51.81% were randomized to MMF. Average follow-up ranged from 24 to 72 months. MMF did not significantly reduce the incidences of end-stage renal disease (ESRD; RR 0.71; 95% CI 0.22-2.34; p=0.58; I2=53%; Fig. 1A) or doubling of serum creatinine (RR 0.53; 95% CI 0.18-1.56; p=0.25; I2=63%; Fig. 1B) as compared with placebo or standard of care in patients with IgAN.

Conclusion

In this meta-analysis of RCTs, there was no significant difference between MMF and placebo or standard of care in terms of ESRD and doubling of serum creatinine in patients with IgAN.

There was no significant difference between groups in terms of ESRD and doubling of serum creatinine.